VCYT Q3 2023 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+19.2% YoY

Gross Profit

$62M69.4% margin

Operating Income

-$32M-35.2% margin

Net Income

-$30M-32.9% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$11M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$71M

Stockholders' Equity

$1.1B

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$76M	+19.2%
Gross Profit	$62M	$50M	+26.0%
Operating Income	-$32M	-$10M	-227.9%
Net Income	-$30M	-$9M	-239.5%

Revenue Segments

Testing

$82M91%

Biopharmaceutical And Other

$4M5%

Product

$4M4%